These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 28109882)

  • 61. Update on progress controlling yellow fever in Africa, 2004-2008.
    Wkly Epidemiol Rec; 2008 Dec; 83(50):450-8. PubMed ID: 19069294
    [No Abstract]   [Full Text] [Related]  

  • 62. Yellow fever: a disease that has yet to be conquered.
    Barrett AD; Higgs S
    Annu Rev Entomol; 2007; 52():209-29. PubMed ID: 16913829
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Yellow Fever: A Perennial Threat.
    Tuells J; Henao-Martínez AF; Franco-Paredes C
    Arch Med Res; 2022 Nov; 53(7):649-657. PubMed ID: 36404585
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Shortage of vaccines during a yellow fever outbreak in Guinea.
    Nathan N; Barry M; Van Herp M; Zeller H
    Lancet; 2001 Dec 22-29; 358(9299):2129-30. PubMed ID: 11784630
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Yellow Fever: Integrating Current Knowledge with Technological Innovations to Identify Strategies for Controlling a Re-Emerging Virus.
    Kleinert RDV; Montoya-Diaz E; Khera T; Welsch K; Tegtmeyer B; Hoehl S; Ciesek S; Brown RJP
    Viruses; 2019 Oct; 11(10):. PubMed ID: 31627415
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Reemergence of yellow fever in Ethiopia after 50 years, 2013: epidemiological and entomological investigations.
    Lilay A; Asamene N; Bekele A; Mengesha M; Wendabeku M; Tareke I; Girmay A; Wuletaw Y; Adossa A; Ba Y; Sall A; Jima D; Mengesha D
    BMC Infect Dis; 2017 May; 17(1):343. PubMed ID: 28506254
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The epidemiology of yellow fever in Africa.
    Mutebi JP; Barrett AD
    Microbes Infect; 2002 Nov; 4(14):1459-68. PubMed ID: 12475636
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Yellow fever].
    Wiercińska-Drapało A
    Przegl Epidemiol; 2004; 58 Suppl 1():101-5. PubMed ID: 15807166
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Yellow Fever Remains a Potential Threat to Public Health.
    Vasconcelos PF; Monath TP
    Vector Borne Zoonotic Dis; 2016 Aug; 16(8):566-7. PubMed ID: 27400066
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Existing and potential infection risk zones of yellow fever worldwide: a modelling analysis.
    Shearer FM; Longbottom J; Browne AJ; Pigott DM; Brady OJ; Kraemer MUG; Marinho F; Yactayo S; de Araújo VEM; da Nóbrega AA; Fullman N; Ray SE; Mosser JF; Stanaway JD; Lim SS; Reiner RC; Moyes CL; Hay SI; Golding N
    Lancet Glob Health; 2018 Mar; 6(3):e270-e278. PubMed ID: 29398634
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Yellow fever vaccines and international travelers.
    Barnett ED; Wilder-Smith A; Wilson ME
    Expert Rev Vaccines; 2008 Jul; 7(5):579-87. PubMed ID: 18564013
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Repetitive dengue outbreaks in East Africa: A proposed phased mitigation approach may reduce its impact.
    Baba M; Villinger J; Masiga DK
    Rev Med Virol; 2016 May; 26(3):183-96. PubMed ID: 26922851
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Yellow fever outbreak in Brazil: the puzzle of rapid viral spread and challenges for immunisation.
    Possas C; Lourenço-de-Oliveira R; Tauil PL; Pinheiro FP; Pissinatti A; Cunha RVD; Freire M; Martins RM; Homma A
    Mem Inst Oswaldo Cruz; 2018 Sep; 113(10):e180278. PubMed ID: 30427974
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Surveillance system for adverse events following immunization against yellow fever in Burkina Faso in 2008. Good practice recommendations].
    Yaméogo TM; Breugelmans JG; Kambou JL; Badolo O; Tiendrebéogo S; Traoré E; Avokey F; Yactayo S
    Med Trop (Mars); 2009 Aug; 69(4):320-1. PubMed ID: 19725376
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast.
    Fitzner J; Coulibaly D; Kouadio DE; Yavo JC; Loukou YG; Koudou PO; Coulombier D
    Vaccine; 2004 Nov; 23(2):156-62. PubMed ID: 15531032
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Yellow fever: new recommendations].
    Rochat L; Genton B
    Rev Med Suisse; 2014 May; 10(429):1014-9. PubMed ID: 24908746
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Persistence of Yellow fever virus outside the Amazon Basin, causing epidemics in Southeast Brazil, from 2016 to 2018.
    Rezende IM; Sacchetto L; Munhoz de Mello É; Alves PA; Iani FCM; Adelino TÉR; Duarte MM; Cury ALF; Bernardes AFL; Santos TA; Pereira LS; Dutra MRT; Ramalho DB; de Thoisy B; Kroon EG; Trindade GS; Drumond BP
    PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006538. PubMed ID: 29864115
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Yellow fever vaccination coverage following massive emergency immunization campaigns in rural Uganda, May 2011: a community cluster survey.
    Bagonza J; Rutebemberwa E; Mugaga M; Tumuhamye N; Makumbi I
    BMC Public Health; 2013 Mar; 13():202. PubMed ID: 23497254
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tolerance and humoral immune response to the yellow fever vaccine in sickle cell disease children treated with hydroxyurea: a multicentre prospective study.
    Koehl B; Aupiais C; Schinckel N; Mornand P; Odièvre MH; Niakate A; Brousse V; Ithier G; Missud F; Holvoet L; Benkerrou M; Sorge F; Faye A
    J Travel Med; 2021 Apr; 28(3):. PubMed ID: 33550421
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Duration of post-vaccination immunity against yellow fever in adults.
    Collaborative group for studies on yellow fever vaccines
    Vaccine; 2014 Sep; 32(39):4977-84. PubMed ID: 25090646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.